Please assess the completion status of the following clinical trial:

Trial Title: Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Hospitalized with coronavirus disease 2019 (COVID-19) pneumonia confirmed by World Health Organization criteria.~* Oxygen saturation ≤ 94% at room air or arterial partial pressure of oxygen/fraction of inspired oxygen \< 300 mm Hg and \> 200 mm Hg.~* Negative influenza test.~* Lymphocyte counts \< 10\^3/μL and the presence of at least one of the following markers of hyperinflammation within 1 day prior to VIB7734 administration:~  * Elevated high sensitivity C-reactive protein (hsCRP) \> 50 mg/L~ * Ferritin \> 500 ng/mL~ * Lactate dehydrogenase (LDH) \> 300 U/L~ * D-dimers \> 500 ng/mL~NOTE: Other protocol defined inclusion criteria apply~Key Exclusion Criteria:~* Respiratory failure requiring mechanical ventilation.~* In the opinion of the Investigator, progression to mechanical ventilation or death is imminent and inevitable within the next 24 hours.~* Valid Do Not Intubate (DNI) or Do Not Resuscitate (DNR) order.~* Anticipated duration of hospital stay \< 72 hours.~* History of allergy or hypersensitivity reaction to any component of the IP.~* Participation in another clinical study with an IP within 4 weeks prior to Day 1 or within 5 half-lives of the IP, whichever is longer. (Participation in COVID-19 antiviral or antimalarial trials may be permitted after discussion with the Medical Monitor).~* Liver cirrhosis or liver failure.~* Known human immunodeficiency virus infection.~* Known hepatitis B or known hepatitis C infection in the absence of a history of curative therapy.~* Known or suspect active or latent tuberculosis infection.~* Active bacterial, fungal, viral, or other infection (besides COVID-19).~* Clinically significant cardiac disease within 6 months.~* History of severely impaired respiratory function at baseline (not related to COVID-19) based on requirement for home oxygen of \> 4 L/min or based on other medical history known to the Investigator.~* History of cancer within 12 months of enrollment.~* Receipt of chemotherapy, biologic immunomodulators (including JAK inhibitors), or immunosuppressive therapies within 8 weeks of enrollment, or receipt of rituximab or other B cell-depleting mAb therapy within 6 months.~NOTE: Other protocol defined exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- VIB7734 Dose (Type: EXPERIMENTAL): Participants will receive a single subcutaneous dose of VIB7734.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a single subcutaneous dose of placebo (saline) matched to single dose of VIB7734.

Based on this trial design, predict the completion outcome and termination type (if applicable).